Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MCRB – Seres Therapeutics, Inc.

Seres Therapeutics, Inc.
MCRB
$1.47
Name : Seres Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $14,985,676.00
EPSttm : -5.01
finviz dynamic chart for MCRB
Seres Therapeutics, Inc.
$1.47
5.78%
$0.09
MCRB — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.01

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

EPS Last/This Y

-4.16

EPS This/Next Y

-1.43

Price

1.56

Target Price

17

Analyst Recom

1

Performance Q

-66.95

Upside

-10,959.0%

Beta

0.56

Ticker: MCRB




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-12MCRB2.680.350.004932
2026-10-13MCRB2.550.340.004949
2026-10-14MCRB2.430.330.004889
2026-10-15MCRB2.550.330.004891
2026-10-16MCRB2.470.330.004891
2026-10-19MCRB2.430.360.004220
2026-10-20MCRB2.370.360.004220
2026-10-21MCRB2.30.420.004424
2026-10-22MCRB2.10.410.054524
2026-10-23MCRB2.10.410.004564
2026-10-26MCRB2.010.391.004659
2026-10-27MCRB1.810.352.754511
2026-10-28MCRB1.80.380.004661
2026-10-29MCRB1.990.370.004681
2026-10-30MCRB1.76990.360.004836
2026-11-02MCRB1.830.320.005319
2026-11-03MCRB1.9550.310.005311
2026-11-04MCRB2.110.310.005318
2026-11-05MCRB2.060.300.005410
2026-11-06MCRB1.970.300.005410
2026-11-09MCRB1.70.300.005410
2026-11-10MCRB1.620.300.005410
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-12MCRB2.68-100.0- -3.52
2026-10-13MCRB2.54-100.0- -3.52
2026-10-14MCRB2.44-100.0- -3.52
2026-10-15MCRB2.57-100.0- -3.52
2026-10-16MCRB2.51-100.0- -3.52
2026-10-19MCRB2.42-100.0- -3.52
2026-10-20MCRB2.42-100.0- -3.52
2026-10-21MCRB2.33-100.0- -3.52
2026-10-22MCRB2.12-100.0- -3.52
2026-10-23MCRB2.10-100.0- -3.52
2026-10-26MCRB2.02-100.0- -3.52
2026-10-27MCRB1.81-100.0- -3.52
2026-10-28MCRB1.78-100.0- -3.52
2026-10-29MCRB2.00-100.0- -3.52
2026-10-30MCRB1.76-100.0- -3.52
2026-11-02MCRB1.84-100.0- -3.52
2026-11-03MCRB1.96-100.0- -3.52
2026-11-04MCRB2.09-100.0- -3.52
2026-11-05MCRB2.09-100.0- -3.52
2026-11-06MCRB2.0142.3- -3.52
2026-11-09MCRB1.7142.3- -3.52
2026-11-10MCRB1.5642.3- -3.52
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-12MCRB-0.04-0.924.17
2026-10-13MCRB-0.04-0.924.17
2026-10-14MCRB-0.04-0.924.17
2026-10-15MCRB-0.04-0.924.17
2026-10-16MCRB-0.04-0.924.17
2026-10-19MCRB-0.04-0.924.14
2026-10-20MCRB-0.04-0.924.14
2026-10-21MCRB-0.04-0.924.14
2026-10-22MCRB-0.04-0.924.14
2026-10-23MCRB-0.04-0.924.14
2026-10-26MCRB-0.04-0.844.14
2026-10-27MCRB-0.04-0.844.11
2026-10-28MCRB-0.04-0.844.11
2026-10-29MCRB-0.04-0.844.11
2026-10-30MCRB-0.04-0.844.11
2026-11-02MCRB-0.04-0.704.11
2026-11-03MCRB-0.04-0.704.11
2026-11-05MCRB-0.04-0.704.11
2026-11-06MCRB-0.04-0.704.11
2026-11-09MCRB-0.04-0.814.01
2026-11-10MCRB-0.04-0.814.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-1.06

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

Insider Transactions

-0.04

Institutional Transactions

-0.81

Beta

0.56

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

Fair Value

Quality Score

13

Growth Score

20

Sentiment Score

15

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.3

Target Price

17

P/E

Forward P/E

PEG

P/S

7.5

P/B

0.73

P/Free Cash Flow

EPS

-4.84

Average EPS Est. Cur. Y​

-3.52

EPS Next Y. (Est.)

-4.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2209.55

Relative Volume

0.54

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

4

EPS 1 30Days Diff

4

EBIT Estimation

◆ MCRB Healthcare
$1.56
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
7/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
7/10
RSI
25.3
Range 1M
0.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
33 /100
WEAK
Momentum
8/25
Growth
17/30
Estimates
0/20
Inst/Vol
0/15
Options
8/10
EPS Yr
-700%
EPS NY
35%
52W%
0%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +989.7% upside
Quality
3/30
Valuation
16/30
Growth
12/25
Stability
2/10
LT Trend
4/5
Upside
+989.7%
Quality
13
MCRB — P/E HistoricalBiotechnology
Seres Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 66
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB

Latest News

—
Caricamento notizie per MCRB…
stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today
news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance
stock history MCRB – Seres Therapeutics, Inc. invest stock market
stock prices MCRB premarket after hours
ticker MCRB fair value insiders trading